Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), linear decrease (Expand Search), clinical areas (Expand Search)
clinical case » clinical cases (Expand Search), clinical care (Expand Search), clinical course (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), linear decrease (Expand Search), clinical areas (Expand Search)
clinical case » clinical cases (Expand Search), clinical care (Expand Search), clinical course (Expand Search)
-
1841
Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
1842
-
1843
Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
1844
-
1845
-
1846
-
1847
-
1848
Transition probabilities and class sizes for three-step LTA model (N = 432).
Published 2025Subjects: -
1849
-
1850
-
1851
Data Sheet 1_Analysis of epidemiology and nomogram construction for prediction and clinical decision-making in gliomas.pdf
Published 2025“…The age-adjusted incidence rate of gliomas decreased from 4.42 per 100,000 persons in 2000 to 3.81 per 100,000 persons in 2019 [APC of -0.53 (95%CI, -0.71 to -0.34)]. …”
-
1852
Case information collected in this study.
Published 2024“…Benign tumors were more common in younger dogs, while malignant tumors predominated in older dogs, accounting for 89.9% of the cases. Early surgical intervention significantly improved survival and quality of life. …”
-
1853
-
1854
-
1855
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Published 2025“…Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRas<sup>G12C</sup>, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. …”
-
1856
-
1857
-
1858
-
1859
-
1860